UCB Acquires Candid Therapeutics for Up to $2.2 Billion: The T‑Cell Engager Bet That Could Redefine Immunology
UCB Acquires Candid Therapeutics for Up to $2.2 Billion: The T‑Cell Engager Bet That Could Redefine Immunology The Sunday Evening News That Quietly Reshaped Immunology Last Sunday evening, while most of us were winding down the weekend, the biopharmaceutical world witnessed a seismic moment, though it didn’t arrive with the fanfare you’d expect for a deal of this magnitude. UCB, the Belgian pharma with a market cap hovering around $4 billion, sent out a press release confirming it had signed a definitive agreement to acquire Candid Therapeutics, a privately held San Diego biotech, in a transaction valued at up to $2.2 billion . If you blinked, you might have missed it. But you shouldn’t. Because this isn’t just a line‑item in a pharma M&A database. This deal represents a deliberate, quietly confident bet that T‑cell engagers — a technology most people still associate exclusively with oncology, could become the backbone of how we treat severe autoimmune d...